4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$23.25 USD
-0.28 (-1.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $23.21 -0.04 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for 4D Molecular Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 288 | 214 | 248 | 277 | 50 |
Receivables | 0 | 0 | 0 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 7 | 8 | 4 | 2 |
Total Current Assets | 297 | 221 | 256 | 283 | 53 |
Net Property & Equipment | 20 | 22 | 14 | 5 | 5 |
Investments & Advances | 11 | 5 | 68 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 340 | 262 | 353 | 288 | 58 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 5 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 9 | 8 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 3 | 7 | 6 |
Total Current Liabilities | 19 | 16 | 16 | 17 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 2 | 13 | 14 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 2 | 105 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 32 | 31 | 34 | 32 | 131 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 723 | 547 | 527 | 392 | 6 |
Retained Earnings | -415 | -314 | -207 | -136 | -79 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 308 | 231 | 319 | 256 | -73 |
Total Liabilities & Shareholder's Equity | 340 | 262 | 353 | 288 | 58 |
Total Common Equity | 308 | 231 | 319 | 256 | -73 |
Shares Outstanding | 42.70 | 32.30 | 32.10 | 25.20 | NA |
Book Value Per Share | 7.21 | 7.16 | 9.94 | 10.17 | 0.00 |
Fiscal Year End for 4D Molecular Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 288 | 320 | 310 | 200 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 9 | 7 | 7 |
Total Current Assets | NA | 297 | 328 | 318 | 207 |
Net Property & Equipment | NA | 20 | 21 | 21 | 22 |
Investments & Advances | NA | 11 | 0 | 0 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 340 | 362 | 353 | 244 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 5 | 3 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 10 | 7 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 1 | 1 |
Total Current Liabilities | NA | 19 | 18 | 14 | 11 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 32 | 32 | 27 | 25 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 723 | 712 | 698 | 562 |
Retained Earnings | NA | -415 | -383 | -373 | -343 |
Other Equity | NA | 0 | 1 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 308 | 330 | 325 | 219 |
Total Liabilities & Shareholder's Equity | NA | 340 | 362 | 353 | 244 |
Total Common Equity | 0 | 308 | 330 | 325 | 219 |
Shares Outstanding | 49.70 | 42.70 | 42.00 | 33.20 | 32.20 |
Book Value Per Share | 0.00 | 7.21 | 7.86 | 9.79 | 6.79 |